MX337082B - Anticuerpos humanos para proteina 4 de tipo angiopoyetina humana. - Google Patents

Anticuerpos humanos para proteina 4 de tipo angiopoyetina humana.

Info

Publication number
MX337082B
MX337082B MX2012007460A MX2012007460A MX337082B MX 337082 B MX337082 B MX 337082B MX 2012007460 A MX2012007460 A MX 2012007460A MX 2012007460 A MX2012007460 A MX 2012007460A MX 337082 B MX337082 B MX 337082B
Authority
MX
Mexico
Prior art keywords
diseases
human
protein
hangptl4
antibodies
Prior art date
Application number
MX2012007460A
Other languages
English (en)
Other versions
MX2012007460A (es
Inventor
W Mark Sleeman
Viktoria Gusarova
Jee H Kim
Gang Chen
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2012007460A publication Critical patent/MX2012007460A/es
Publication of MX337082B publication Critical patent/MX337082B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

La presente invención se refiere a un anticuerpo humano aislado o fragmento de unión a antígeno del mismo, que se une específicamente a proteína 4 de tipo angiopoyetina humana (hANGPTL4), que comprende una región 1 determinante de complementariedad de cadena pesada (HCDR1) /HCDR2/HCDR3 que comprende una combinación de secuencia de amino ácido de SEQ ID NO.: 28/30/32, y una región 1 determinante de complementariedad de cadena ligera (LCDR1)/LCDR2/LCDR3 que comprende una combinación de secuencia de amino ácido de SEC ID NO.: 36/38/40.
MX2012007460A 2009-12-24 2010-12-23 Anticuerpos humanos para proteina 4 de tipo angiopoyetina humana. MX337082B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US29009209P 2009-12-24 2009-12-24
US30635910P 2010-02-19 2010-02-19
US32831610P 2010-04-27 2010-04-27
US34927310P 2010-05-28 2010-05-28
US35612610P 2010-06-18 2010-06-18
PCT/US2010/061987 WO2011079257A2 (en) 2009-12-24 2010-12-23 Human antibodies to human angiopoietin-like protein 4

Publications (2)

Publication Number Publication Date
MX2012007460A MX2012007460A (es) 2012-08-23
MX337082B true MX337082B (es) 2016-02-11

Family

ID=43629324

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007460A MX337082B (es) 2009-12-24 2010-12-23 Anticuerpos humanos para proteina 4 de tipo angiopoyetina humana.

Country Status (30)

Country Link
US (2) US8354103B2 (es)
EP (1) EP2516466B1 (es)
JP (2) JP6000855B2 (es)
KR (1) KR101842570B1 (es)
CN (1) CN102741284A (es)
AR (1) AR079708A1 (es)
AU (1) AU2010336369C1 (es)
BR (1) BR112012017765A2 (es)
CA (1) CA2785158C (es)
CY (1) CY1118898T1 (es)
DK (1) DK2516466T3 (es)
ES (1) ES2628135T3 (es)
HR (1) HRP20170524T1 (es)
HU (1) HUE034722T2 (es)
IL (1) IL220402A (es)
JO (1) JO3274B1 (es)
LT (1) LT2516466T (es)
MX (1) MX337082B (es)
NZ (1) NZ600768A (es)
PL (1) PL2516466T3 (es)
PT (1) PT2516466T (es)
RS (1) RS56009B1 (es)
RU (1) RU2580045C2 (es)
SG (1) SG181784A1 (es)
SI (1) SI2516466T1 (es)
SM (1) SMT201700280T1 (es)
TW (1) TWI488643B (es)
UY (1) UY33144A (es)
WO (1) WO2011079257A2 (es)
ZA (1) ZA201204507B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
MX347602B (es) 2011-01-28 2017-05-03 Sanofi Biotechnology Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9.
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
EP2757875B2 (en) * 2011-09-19 2023-03-22 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
EP2836232A4 (en) * 2012-04-13 2016-03-16 Univ Johns Hopkins TREATMENT OF ISCHEMIC RETINOPATHY
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
JP6309521B2 (ja) 2012-08-13 2018-04-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ｐＨ依存性結合特性を有する抗ＰＣＳＫ９抗体
GB201301313D0 (en) * 2013-01-25 2013-03-06 Univ Singapore Respiratory Tract Infections
CN105579469A (zh) 2013-06-10 2016-05-11 默沙东公司 Cmv中和抗原结合蛋白
KR101538787B1 (ko) * 2013-06-27 2015-07-22 인하대학교 산학협력단 췌장염 진단용 바이오 마커 조성물
EP3092491B1 (en) * 2014-01-07 2018-10-31 Bioatla, LLC Proteins targeting orthologs
TW201613977A (en) 2014-08-07 2016-04-16 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
TN2017000019A1 (en) 2014-08-07 2018-07-04 Novartis Ag Angiopoietin-like 4 antibodies and methods of use.
US9556225B2 (en) * 2014-10-15 2017-01-31 Uniao Quimica Farmaceutica Nacional S/A Peptide stimulator of cell survival and proliferation
WO2016181409A1 (en) 2015-05-11 2016-11-17 Cadila Healthcare Limited Saroglitazar magnesium for the treatment of chylomicronemia syndrome -
WO2017011929A1 (zh) * 2015-07-17 2017-01-26 北京大学第一医院 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
US10772956B2 (en) 2015-08-18 2020-09-15 Regeneron Pharmaceuticals, Inc. Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
US10385017B2 (en) 2015-10-14 2019-08-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
JP7133551B2 (ja) 2016-11-17 2022-09-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ａｎｇｐｔｌ８抗体を用いて肥満を処置する方法
EP3565598A4 (en) 2017-01-03 2020-10-28 Trellis Bioscience, LLC NATIVE HUMAN ANTIBODIES FOR TIM-3 AND B7-H3 IMMUNE CHECKPOINT MODULATION TARGETS
US20190031774A1 (en) 2017-06-09 2019-01-31 Sanofi Biotechnology Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
US20240317892A1 (en) * 2019-03-20 2024-09-26 Javelin Oncology, Inc Anti-adam12 antibodies and chimeric antigen receptors, and compositions and methods comprising
JP2022521958A (ja) 2019-08-29 2022-04-13 榮昌生物制薬（烟台）股▲フン▼有限公司 抗ｐｄ－ｌ１抗体及びその応用
CN115175685B (zh) * 2019-12-09 2024-12-13 艾姆皮瑞克公司 用于治疗血管生成素样4(angptl4)相关疾病的寡核苷酸
HRP20231031T1 (hr) 2020-02-26 2023-12-22 Vir Biotechnology, Inc. Protutijela protiv sars-cov-2
WO2022006555A2 (en) * 2020-07-02 2022-01-06 Gigagen, Inc. BISPECIFIC ANTIGEN BINDING PROTEINS TARGETING PD-L1 AND TGF-β AND METHODS OF USE
WO2022006370A2 (en) * 2020-07-02 2022-01-06 Mablytics, Inc. Cell-binding proteins and methods of use
CN119343148A (zh) * 2022-06-10 2025-01-21 南洋理工大学 使用angptl4拮抗剂治疗肝纤维化、炎症或相关疾病的方法
TW202415409A (zh) * 2022-08-02 2024-04-16 中國商諾納生物（蘇州）有限公司 Msln抗體藥物複合體
CN117535353A (zh) * 2023-10-11 2024-02-09 首都医科大学附属北京潞河医院 一种糖尿病视网膜病变模型的建立方法及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
KR101017301B1 (ko) * 2004-12-21 2011-02-28 메드임뮨 리미티드 앤지오포이에틴-2에 대한 항체 및 그의 용도
CA2594233C (en) * 2005-01-07 2015-02-24 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against angiopoietin-like protein 4 (angptl4 )
NZ568739A (en) 2005-12-16 2010-09-30 Regeneron Pharma Therapeutic methods for inhibiting tumor growth with delta-like ligand 4 antagonists
AU2007227251A1 (en) * 2006-03-20 2007-09-27 Amgen Fremont, Inc. Antibodies directed to angiopoietin-like protein 4 and uses thereof
PL2374818T3 (pl) 2006-06-02 2013-05-31 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).

Also Published As

Publication number Publication date
DK2516466T3 (en) 2017-05-15
LT2516466T (lt) 2017-05-25
EP2516466A2 (en) 2012-10-31
BR112012017765A2 (pt) 2017-06-20
AU2010336369C1 (en) 2015-08-27
WO2011079257A2 (en) 2011-06-30
TWI488643B (zh) 2015-06-21
KR101842570B1 (ko) 2018-03-28
PL2516466T3 (pl) 2017-09-29
AR079708A1 (es) 2012-02-15
CA2785158A1 (en) 2011-06-30
SI2516466T1 (sl) 2017-06-30
SG181784A1 (en) 2012-07-30
ES2628135T3 (es) 2017-08-01
JP2015145424A (ja) 2015-08-13
US20110159015A1 (en) 2011-06-30
KR20120104613A (ko) 2012-09-21
JP6000855B2 (ja) 2016-10-05
AU2010336369A1 (en) 2012-07-12
HRP20170524T1 (hr) 2017-06-02
MX2012007460A (es) 2012-08-23
ZA201204507B (en) 2013-02-27
NZ600768A (en) 2014-09-26
UY33144A (es) 2011-06-30
AU2010336369B2 (en) 2015-06-04
RS56009B1 (sr) 2017-09-29
RU2580045C2 (ru) 2016-04-10
EP2516466B1 (en) 2017-03-15
US8354103B2 (en) 2013-01-15
JP2013515486A (ja) 2013-05-09
HUE034722T2 (en) 2018-02-28
CY1118898T1 (el) 2018-01-10
SMT201700280T1 (it) 2017-07-18
RU2012131547A (ru) 2014-01-27
US9120851B2 (en) 2015-09-01
JO3274B1 (ar) 2018-09-16
PT2516466T (pt) 2017-06-06
US20130266574A1 (en) 2013-10-10
CN102741284A (zh) 2012-10-17
IL220402A (en) 2016-10-31
WO2011079257A3 (en) 2011-08-18
CA2785158C (en) 2018-07-24
TW201132354A (en) 2011-10-01

Similar Documents

Publication Publication Date Title
MX337082B (es) Anticuerpos humanos para proteina 4 de tipo angiopoyetina humana.
SG195165A1 (en) Anti-angptl3 antibodies and uses thereof
MA44764B1 (fr) Méthodes de traitement de patients présentant une hypercholestérolémie familiale
MX386832B (es) Inhibidor angptl8 e inhibidor angptl3 para usarse en el tratamiento de hiperlipidemia.
NZ703481A (en) Cd37-binding molecules and immunoconjugates thereof
NZ600974A (en) Binding members for human cytomegalovirus
EA201500064A1 (ru) Активаторы ampk и их применение в терапевтических целях
UA102775C2 (uk) Спосіб лікування болю із застосуванням анти-ngf антитіла
NZ587292A (en) Use of anti-CGRP (calcitonin gene-related peptide) antagonists to treat chronic pain
MY156316A (en) Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
EA201490004A1 (ru) Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
EA033405B1 (ru) Изолированное антитело, которое индуцирует опосредованную фактором роста фибробластов 21 (fgf21) передачу сигнала
WO2010054265A3 (en) Monoclonal antibodies to fibroblast growth factor receptor 2
UA101681C2 (ru) Изолированное антитело, которое специфически связывается с рецептором фактора роста фибробластов -3 и фармацевтическая композиция, которая содержит указанное антитело
UA103916C2 (xx) Антитіло проти dkk-1$антитело против dkk-1
WO2009036149A3 (en) Methods for treatment of degenerative disease associated with apoptosis
EA201101643A1 (ru) ВАРИАНТЫ ПРИМЕНЕНИЯ IL-1β АНТИТЕЛ И ИХ СВЯЗЫВАЮЩИХ ФРАГМЕНТОВ В СЕРДЕЧНО-СОСУДИСТОЙ СИСТЕМЕ
IL213213A (en) Use of Human Monoclonal Antibodies or Antigen-Related Fragments Specific to Human Ligand Protein Protein in the Manufacture of Medicines to Prevent and / or Treat Pampigos
MX2024008740A (es) Anticuerpo humanizado que tiene especificidad de union por la integrina \03b14\03b27 humana para usarse en la prevencion de la enfermedad del injerto contra huesped de grado iii o iv.
MY149863A (en) Delayed-release glucocorticoid treatment of rheumatoid disease
PH12012501279A1 (en) Human antibodies to human angiopoietin-like protein 4
TN2013000490A1 (en) Anti-angptl3 antibodies and uses thereof
NZ596218A (en) Bssl antagonists for treatment of inflammatory diseases
UA108207C2 (xx) Високоафінне людське антитіло до людського ангіопоетину-2

Legal Events

Date Code Title Description
FG Grant or registration